Pharmaceutical Technology on MSN22h
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitisChina's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback